Phage Therapy for UTI: All 16 Patients Cleared in Phase 2

A 2024 trial published in The Lancet Infectious Diseases reported something unusual. Every single one of the 16 patients on the optimal dose of an engineered phage cocktail cleared their E. coli UTI by day 10. Bacterial counts in urine dropped within 4 hours of the first dose. No serious adverse events [1].

The trial was small. The design was open-label, not blinded. The patients had uncomplicated infections, not the gnarly recurrent cases that drive most patients to look beyond antibiotics. But this is the strongest controlled human data phage therapy for UTI has ever produced, and it lands at a moment when recurrent UTIs are getting harder to treat with the antibiotic toolkit we have.

Key Takeaways

• The 2024 ELIMINATE Phase 2 trial of LBP-EC01 reported 100% symptom resolution by day 10 in the optimal-dose group (16 of 16 patients)
• Phages kill bacteria through a different mechanism than antibiotics, so antibiotic resistance does not confer phage resistance
• The earlier Leitner 2021 RCT (113 patients) found phages were non-inferior to antibiotics and placebo, but not superior — the evidence is more nuanced than the headlines
• A new UCSD Phase 1/2 trial in kidney transplant recipients with recurrent UTI started recruiting in 2025 (NCT06409819)
• Phage therapy is not approved for UTI in the US, Australia, or Europe — access is via clinical trials or compassionate use only

Why This Is Suddenly Newsworthy

Phage therapy is not new. Soviet and Polish researchers were treating bacterial infections with bacteriophages in the 1920s, before penicillin existed. The Eliava Institute in Tbilisi, Georgia, has been doing it continuously for nearly a century.

What changed in 2024 is the engineering. Locus Biosciences took six naturally occurring phages that target E. coli, then used CRISPR-Cas3 to enhance their killing efficiency. The Cas3 system carries an extra payload of bacterial-DNA-shredding capability into each infected bacterial cell. When the phage hijacks the bacterium, the Cas3 finishes the job even if the phage’s natural replication is disrupted.

This is what makes LBP-EC01 different from the phages used at Eliava for decades. It’s a designed therapeutic with a defined composition, manufactured to pharmaceutical standards, with a regulatory pathway in the US. That changes the conversation from “interesting Eastern European folk medicine” to “Phase 3 candidate.”

How Phage Therapy Actually Works

Phages are viruses that exclusively infect bacteria. Each phage is highly specific — usually to a single bacterial species, sometimes to particular strains within that species. They cannot infect human cells. There are no human cell receptors that match phage tail proteins.

The killing mechanism is simple. A phage binds to a specific receptor on the bacterial surface, injects its genetic material, hijacks the bacterial machinery to produce hundreds of copies of itself, then bursts the cell open to release them. Each cycle takes 20-40 minutes. With enough starting phages, a bacterial population can crash within a few hours.

For a UTI, this matters in three ways:

Specificity. Antibiotics like ciprofloxacin or trimethoprim hit your gut and vaginal microbiome along with the UTI pathogen. Phages target only the offending bacterial strain, leaving the rest of your microbiome intact. This is one reason phage-treated patients in case reports have not gone on to develop antibiotic-associated diarrhea or thrush.

Biofilm penetration. Many recurrent UTI pathogens live in biofilms on the bladder wall or inside catheter lumens. Antibiotics struggle to penetrate biofilms, which is part of why recurrent UTI is such a stubborn problem. Some phages produce enzymes called depolymerases that actively dissolve biofilm matrix.

Self-amplifying dose. Every infected bacterial cell becomes a factory producing more phages. The therapeutic dose grows as long as target bacteria are present, then disappears when they are not. No antibiotic does this.

The Evidence, Graded

The strongest data: ELIMINATE Phase 2 (Locus Biosciences, 2024)

This is the headline study. Published in The Lancet Infectious Diseases in August 2024, the trial randomised 39 women with uncomplicated E. coli UTI to three different LBP-EC01 dosing regimens. The optimal arm received 2 days of intraurethral phage (2 × 10¹² PFUs), 3 days of IV phage (1 × 10¹⁰ PFUs), and oral trimethoprim-sulfamethoxazole twice daily [1].

Results from the 16 patients on the optimal regimen:

• Rapid E. coli reduction in urine within 4 hours of first dose
• 100% symptom resolution by the day 10 test-of-cure visit
• 44 adverse events across 18 patients in the safety population, none serious

Caveats: open-label design, small numbers, uncomplicated infections only, and concurrent antibiotic use makes it impossible to isolate the phage contribution from the SMX-TMP contribution. Part 2 of ELIMINATE is now enrolling as a placebo-controlled registrational trial. That readout is the one that matters for FDA approval.

The honest reality check: Leitner et al. 2021

The only randomised, double-blind, placebo-controlled trial of phage therapy for UTI to date. Conducted at the Eliava Institute in Tbilisi, it randomised 113 men undergoing transurethral prostate resection to bacteriophage cocktail, broad-spectrum antibiotic, or placebo bladder instillation [2].

The result was less exciting than the headlines suggested. Phage treatment was non-inferior to both antibiotic and placebo for normalising urine cultures at day 7. That sounds fine until you realise placebo also worked, because many of these UTIs would resolve spontaneously. On the secondary endpoint of bacterial count reduction, phages came in third behind antibiotics.

The honest read: this trial did not prove phages work. It proved they did not work meaningfully better than nothing in this specific population.

Case reports and compassionate use

A handful of well-documented case reports show striking individual responses. A 17-year-old kidney transplant recipient with recurrent extended-spectrum beta-lactamase E. coli UTI was treated with personalised phages and remained ESBL-negative through 4 years of follow-up [3]. A 58-year-old with relapsing Klebsiella pneumoniae UTI had 14 months of clean urine cultures after phage therapy [4].

These are encouraging but the format is the weakest tier of evidence. Case reports show what can happen, not what does happen on average.

A 2025 systematic review

A systematic review published in 2025 pooled all available human data on phage therapy for UTI [5]. The conclusion: phages are generally safe, the case-report response rates are high, but the absence of large blinded RCTs means efficacy cannot be claimed with confidence. The authors flagged standardised susceptibility testing, dosing strategy, and route of administration as the biggest unresolved questions.

Study	Year	Design	N	Key finding	Evidence weight
LBP-EC01 ELIMINATE Part 1	2024	Phase 2 open-label RCT	39 (16 in optimal arm)	100% symptom resolution day 10	Strong but unblinded
Leitner et al.	2021	Phase 2/3 RCT, double-blind	113	Non-inferior to antibiotic and placebo	Strongest design, mixed result
Le et al. case report	2022	Single case	1	4-year remission post-ESBL UTI	Anecdotal
Kuipers et al. case report	2019	Single case	1	14 months culture-negative	Anecdotal
Kim et al.	2021	Phase 2 uncontrolled	16	UTI resolution by day 10	Suggestive, no control

Phage Therapy vs Current Options

Most patients reading this are not choosing between phages and nothing. They are choosing between phages (hypothetically, if they could access them) and the prevention tools that already exist.

Option	Evidence level	Mechanism	Best for	Main limitation
Phage therapy (LBP-EC01)	Phase 2 RCT, n=39	Bacterial lysis, biofilm	Antibiotic-resistant E. coli	Not approved, no access
Methenamine hippurate	Phase 3 RCT (ALTAR, n=240)	Urinary antiseptic	Recurrent UTI prevention	Needs acid urine pH
D-Mannose	Multiple RCTs	Blocks E. coli adhesion	E. coli-only UTIs	Modest effect size in 2022 mega-trial
Cranberry	Cochrane review	Anti-adhesion	Mild prevention	~27% reduction, many products underdosed
Vaginal estrogen	RCT in postmenopausal women	Restores flora	Postmenopausal women	Postmenopausal use only
Long-course antibiotic prophylaxis	Strong	Direct bacterial kill	Severe recurrent UTI	Resistance, microbiome damage

The pitch for phages is not that they replace these. The pitch is that they offer something for patients whose UTIs are caused by multi-drug-resistant strains where the existing toolkit is failing. That is a real and growing patient population, but it is not most patients.

The Honest Case Against

A few things bother me about the current state of the evidence.

The Leitner trial is the only randomised double-blind study, and the result was not a clear win for phages. Most of the optimism comes from open-label trials, case reports, and pre-clinical work. In any other therapeutic area we would call this thin.

ELIMINATE Part 1 combined phages with concurrent oral antibiotic. We cannot tell what the phages did versus what the SMX-TMP did. The placebo-controlled Part 2 is what will answer that.

Manufacturing is still hard. Each batch of phages has to be characterised, purity-controlled, and tested for activity against the specific patient’s bacterial isolate. This is not “take two tablets twice daily.” It is closer to personalised oncology in operational complexity.

And the cost will not be small. CRISPR-engineered biologics with hospital-administered IV and intraurethral protocols are not going to be a $30 prescription.

When You Might Actually Encounter This

If you have garden-variety urinary tract infections that respond to standard antibiotics, you will not be offered phage therapy in the next 5 years. The economics and regulatory pathway point at antibiotic-resistant cases first.

The patient groups closest to a real treatment option:

• Multi-drug-resistant E. coli recurrent UTI. This is the ELIMINATE target population. If LBP-EC01 succeeds in Part 2, FDA approval for this indication could come around 2027-2028.
• Kidney transplant recipients with recurrent UTI. The UCSD Phase 1/2 trial (NCT06409819) started recruiting in 2025. Results are expected by 2027.
• Catheter-associated UTI with biofilm. Strong pre-clinical case, no late-stage trials yet.
• Compassionate use for failing patients. Available case-by-case through programs at Yale, UCSD, and a handful of other US academic centres. The Eliava Institute in Georgia treats international patients on a fee basis but the quality of oversight is not equivalent to a regulated trial.

When This Isn’t Enough

Phage therapy is research-stage. If you are currently dealing with a UTI, the recommendation is the same as it has been: treat active infections with the antibiotic your culture and sensitivity testing supports, and pursue prevention through the proven tools.

If your UTIs are recurrent despite best-effort prevention, ask your urologist whether you might qualify for a clinical trial. The current trial registry at clinicaltrials.gov is searchable by location. Compassionate use protocols exist but typically require a referring physician to initiate the application.

Red flags that mean don’t wait for phage therapy and don’t experiment with natural recurrent UTI prevention alone — go to a doctor:

• Fever, flank pain, or back pain (possible kidney involvement)
• Blood in urine that persists or worsens
• Pregnancy with any UTI symptom
• Diabetes with UTI symptoms
• Three or more confirmed UTIs in 12 months — this warrants a urology referral and a culture history review

What People Ask

When will phage therapy for UTI be available in Australia?

Not soon. The TGA has no approved phage therapy product. Even if LBP-EC01 succeeds in US Phase 3 and gets FDA approval in 2027-2028, TGA review usually adds 12-24 months. Realistic earliest availability in Australia: 2029-2030, and only for multi-drug-resistant E. coli indications initially.

Is phage therapy the same as a probiotic?

No. Probiotics are live bacteria that you swallow, hoping they will colonise the gut or vagina and crowd out pathogens. Phages are viruses that kill specific bacteria. Different organisms, different mechanism, different evidence base. There is interesting overlap in the gut-bladder axis work, but they are not interchangeable.

Can you give phages to children for UTI?

Pediatric phage therapy case reports exist but no controlled trials. The 17-year-old in the Le et al. case report received personalised phages for ESBL E. coli UTI successfully. This is the only setting where pediatric phage therapy is happening, and only on compassionate use grounds when standard antibiotics have failed.

How does this compare to fecal microbiota transplant for UTI?

Different strategy entirely. Fecal transplant for UTI tries to restore healthy gut flora that might be seeding pathogens to the urinary tract. Phages directly kill the UTI bacteria. The fecal transplant evidence is earlier and more limited than phage data.

Will bacteria develop resistance to phages?

Yes, this happens in vitro and in animals. The standard response is to use cocktails of multiple phages with different bacterial-surface targets. LBP-EC01 uses six different phages for this reason. Phage resistance also often comes with a fitness cost to the bacteria, meaning resistant strains may be less infectious. This is still an active research question.

What about phage therapy for prostatitis or kidney infection?

No good controlled data. The phage tissue penetration question is harder for prostate (deep tissue) and pyelonephritis (upper tract). Some compassionate use cases have been reported but the published evidence is much thinner than for cystitis.

The Short Version

LBP-EC01 produced the best Phase 2 data phage therapy for UTI has ever generated, but the trial was open-label, the patients had uncomplicated infections, and the regimen included a concurrent antibiotic. The placebo-controlled Part 2 will determine whether phages are an FDA-approvable therapy or another promising compound that fades in late-stage trials.

For now, phage therapy is not a treatment option for most patients with recurrent UTI in Australia, the US, or the UK. The tools that are proven and accessible — methenamine hippurate, D-mannose for E. coli UTIs, vaginal estrogen in postmenopausal women, and NAC for biofilm — still belong on the table first. What changes if Part 2 reads out positive is the option set in 2028 and beyond for patients with antibiotic-resistant infections, where the current toolkit is genuinely failing.

That is the patient group worth watching this research for.

References

1. Kim PJ, Kunkel TJ, Watanabe JH, et al. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. Lancet Infect Dis. 2024;24(11):1300-1311. PubMed

2. Leitner L, Ujmajuridze A, Chanishvili N, et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 2021;21(3):427-436. PubMed

3. Le T, Nang SC, Zhao J, et al. Therapeutic potential of intravenous phage as standalone therapy for recurrent drug-resistant urinary tract infections. Antimicrob Agents Chemother. 2023;67(4):e0003723. PubMed

4. Kuipers S, Ruth MM, Mientjes M, et al. A Dutch case report of successful treatment of chronic relapsing urinary tract infection with bacteriophages in a renal transplant patient. Antimicrob Agents Chemother. 2019;64(1):e01281-19. PubMed

5. Phage therapy in patients with urinary tract infections: a systematic review. Expert Rev Anti Infect Ther. 2025. Article

6. ClinicalTrials.gov. Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients. NCT06409819. Trial